NO20064293L - Anvendelse av TWEAK-modulatorer og inhibitorer for behandling av nevrologiske tilstander - Google Patents
Anvendelse av TWEAK-modulatorer og inhibitorer for behandling av nevrologiske tilstanderInfo
- Publication number
- NO20064293L NO20064293L NO20064293A NO20064293A NO20064293L NO 20064293 L NO20064293 L NO 20064293L NO 20064293 A NO20064293 A NO 20064293A NO 20064293 A NO20064293 A NO 20064293A NO 20064293 L NO20064293 L NO 20064293L
- Authority
- NO
- Norway
- Prior art keywords
- tweak
- treatment
- modulate
- inhibit
- modulators
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04004094A EP1566636A1 (de) | 2004-02-23 | 2004-02-23 | Verwendung von Modulatoren und Inhibitoren von TWEAK zur Behandlung von neurologischen Zuständen |
| PCT/EP2005/001921 WO2005080972A1 (en) | 2004-02-23 | 2005-02-23 | Use of tweak modulators and inhibitors for the treatment of neurological conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20064293L true NO20064293L (no) | 2006-09-22 |
Family
ID=34707372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20064293A NO20064293L (no) | 2004-02-23 | 2006-09-22 | Anvendelse av TWEAK-modulatorer og inhibitorer for behandling av nevrologiske tilstander |
Country Status (16)
| Country | Link |
|---|---|
| EP (2) | EP1566636A1 (de) |
| JP (1) | JP2007532482A (de) |
| KR (1) | KR20070029677A (de) |
| CN (1) | CN1985169A (de) |
| AT (1) | ATE504600T1 (de) |
| AU (1) | AU2005214843A1 (de) |
| BR (1) | BRPI0507959A (de) |
| CA (1) | CA2558770A1 (de) |
| DE (1) | DE602005027322D1 (de) |
| EA (1) | EA200601547A1 (de) |
| IL (1) | IL177285A0 (de) |
| IS (1) | IS8540A (de) |
| MX (1) | MXPA06009518A (de) |
| NO (1) | NO20064293L (de) |
| WO (1) | WO2005080972A1 (de) |
| ZA (1) | ZA200606840B (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA004590B1 (ru) | 1999-01-15 | 2004-06-24 | Байоджен, Инк. | Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина" |
| AU2003224950B2 (en) | 2002-04-09 | 2006-09-14 | Biogen Ma Inc. | Methods for treating tweak-related conditions |
| AU2006214179A1 (en) | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating neurological disorders |
| AU2011239311B2 (en) * | 2005-02-17 | 2014-05-22 | Biogen Ma Inc. | Treating Neurological Disorders |
| WO2006122187A2 (en) | 2005-05-10 | 2006-11-16 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
| WO2006130374A2 (en) | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Tweak binding antibodies |
| WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
| EP1876448A1 (de) * | 2005-09-30 | 2008-01-09 | DIGILAB BioVisioN GmbH | Verfahren und analytische Reagenzien zur Medikamentidentifizierung mittels auf Thiazolidinedionen reagierenden Biomarkern |
| EP2545938A1 (de) | 2007-08-03 | 2013-01-16 | Abbott Biotherapeutics Corp. | Therapeutische Verwendung von Anti-TWEAK-Rezeptorantikörpern |
| WO2011097500A2 (en) * | 2010-02-04 | 2011-08-11 | University Of Louisville Research Foundation, Inc. | The tweak/fn14 system regulates skeletal muscle atrophy and regeneration |
| US8609818B2 (en) | 2011-03-10 | 2013-12-17 | Omeros Corporation | Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4276110A (en) | 1978-11-30 | 1981-06-30 | Yardney Electric Corporation | Method of forming a separator integral with an electrode |
| US6379882B1 (en) * | 1998-09-14 | 2002-04-30 | Elan Pharmaceuticals, Inc. | Method for selecting compounds for treating ischemia-related cellular damage |
| EA004590B1 (ru) * | 1999-01-15 | 2004-06-24 | Байоджен, Инк. | Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина" |
| AU8901901A (en) * | 2000-09-14 | 2002-03-26 | Biogen Inc | Tweak receptor agonists as anti-angiogenic agents background |
-
2004
- 2004-02-23 EP EP04004094A patent/EP1566636A1/de not_active Withdrawn
-
2005
- 2005-02-23 DE DE602005027322T patent/DE602005027322D1/de not_active Expired - Lifetime
- 2005-02-23 BR BRPI0507959-4A patent/BRPI0507959A/pt not_active Application Discontinuation
- 2005-02-23 CN CNA2005800056025A patent/CN1985169A/zh active Pending
- 2005-02-23 AT AT05715497T patent/ATE504600T1/de not_active IP Right Cessation
- 2005-02-23 CA CA002558770A patent/CA2558770A1/en not_active Abandoned
- 2005-02-23 JP JP2006553571A patent/JP2007532482A/ja active Pending
- 2005-02-23 EP EP05715497A patent/EP1721157B1/de not_active Expired - Lifetime
- 2005-02-23 EA EA200601547A patent/EA200601547A1/ru unknown
- 2005-02-23 AU AU2005214843A patent/AU2005214843A1/en not_active Abandoned
- 2005-02-23 MX MXPA06009518A patent/MXPA06009518A/es not_active Application Discontinuation
- 2005-02-23 WO PCT/EP2005/001921 patent/WO2005080972A1/en not_active Ceased
- 2005-02-23 KR KR1020067019381A patent/KR20070029677A/ko not_active Withdrawn
-
2006
- 2006-08-03 IL IL177285A patent/IL177285A0/en unknown
- 2006-08-15 ZA ZA200606840A patent/ZA200606840B/xx unknown
- 2006-09-15 IS IS8540A patent/IS8540A/is unknown
- 2006-09-22 NO NO20064293A patent/NO20064293L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200606840B (en) | 2008-05-28 |
| CA2558770A1 (en) | 2005-09-01 |
| IS8540A (is) | 2006-09-15 |
| DE602005027322D1 (de) | 2011-05-19 |
| WO2005080972A1 (en) | 2005-09-01 |
| JP2007532482A (ja) | 2007-11-15 |
| EP1721157B1 (de) | 2011-04-06 |
| IL177285A0 (en) | 2006-12-10 |
| BRPI0507959A (pt) | 2007-07-17 |
| ATE504600T1 (de) | 2011-04-15 |
| EP1721157A1 (de) | 2006-11-15 |
| EP1566636A1 (de) | 2005-08-24 |
| CN1985169A (zh) | 2007-06-20 |
| AU2005214843A1 (en) | 2005-09-01 |
| KR20070029677A (ko) | 2007-03-14 |
| MXPA06009518A (es) | 2007-03-23 |
| EA200601547A1 (ru) | 2006-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE429645T1 (de) | Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten | |
| ATE376828T1 (de) | Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms | |
| CY1112238T1 (el) | Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων | |
| ATE445415T1 (de) | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung | |
| MA30392B1 (fr) | Composes organiques et leurs utilisations | |
| DE602005015862D1 (de) | Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien | |
| CR8701A (es) | Moduladores canabinoides de tetrahidro-indazol | |
| NO20080969L (no) | 1,2-diarylimidazoler for anvendelse som CBI-modulatorer | |
| ATE534391T1 (de) | 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen | |
| MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
| EA200601547A1 (ru) | Применение модуляторов и ингибиторов tweak для лечения неврологических состояний | |
| IL163026A (en) | Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders | |
| ATE494890T1 (de) | Alpha-aminoamid-derivate zur behandlung von suchtstörungen | |
| IL225745A0 (en) | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds are suitable for the treatment of disorders that respond to dopamine 3d receptor regulation | |
| NO20082214L (no) | 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer | |
| MX2010000956A (es) | Derivados de isoftalamida que inhiben actividad de beta-secretasa. | |
| ATE457309T1 (de) | Modulatoren von peripheren 5-ht-rezeptoren | |
| NO20055563L (no) | Midler for behandlingen av lavere abdominale lidelser | |
| ZA200803532B (en) | Hexahydro-cycloheptapyrazole cannabinoid modulators | |
| EP1988915A4 (de) | Verfahren zur modulierung der zellaktivität und mittel zur verwendung damit | |
| CY1110156T1 (el) | Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης | |
| DK1592446T3 (da) | Inhibering af CD95-ligand/receptorsystemet til behandling af neurologiske lidelser og skader | |
| WO2007029063A3 (en) | Treatment and/or prevention of pervasive developmental disorders | |
| MY141048A (en) | Morpholine derivatives as norepinephrine reuptake inhibitors | |
| ATE427754T1 (de) | Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |